Brief: Marksans Pharma Receives Marketing Authorization For Oxybutynin Hydrochloride Oral Solution
19/06/2025 06:38
June 19 (Reuters) - Marksans Pharma Ltd MARK.NS: RECEIVES MARKETING AUTHORIZATION FOR OXYBUTYNIN HYDROCHLORIDE ORAL SOLUTION RECEIVES AUTHORIZATION FROM UK MEDICINES & HEALTHCARE PRODUCTS REGULATORY AGENCY Source text: ID:nBSEbs1k6z Further company coverage: MARK.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg